SEC Form 10-Q filed by Nuwellis Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

For the quarterly period ended September 30, 2025

OR

 

For the transition period from __________ to __________

 

Commission file number 001-35312

 

 

(Exact Name of Registrant as Specified in its Charter)

 

12988 Valley View Road, Eden Prairie, MN 55344

(Address of Principal Executive Offices) (Zip Code)

 

(952) 345-4200

(Registrant’s Telephone Number, Including Area Code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act:

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

The number of outstanding shares of the registrant’s Common Stock, $0.0001 par value, as of November 7, 2025, was 1,658,799.

 

 

PART I—FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

 

 

See notes to the condensed consolidated financial statements.

 

NUWELLIS, INC. AND SUBSIDIARY

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(in thousands, except per share amounts and weighted average shares outstanding)

 

 

See notes to the condensed consolidated financial statements.

 

NUWELLIS, INC. AND SUBSIDIARY

Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

(Unaudited)

(in thousands, except share amounts)

 

 

 

See notes to the condensed consolidated financial statements.

 

NUWELLIS, INC. AND SUBSIDIARY

Condensed Consolidated Statements of Cash Flows

 

 

 

See notes to the condensed consolidated financial statements.

 

NUWELLIS, INC. AND SUBSIDIARY

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our interim condensed consolidated financial statements and related notes included in Part I, Item 1 of this Quarterly Report on Form 10-Q and the audited consolidated financial statements and related notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in our Annual Report on Form 10-K for the year ended December 31, 2024. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of a variety of factors, including those discussed in Part I, Item 1A “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2024 and in our subsequent filings with the Securities and Exchange Commission (the “SEC”).

 

Unless otherwise specified or indicated by the context, “Nuwellis,” “Company,” “we,” “us,” and “our” refer to Nuwellis, Inc. and its subsidiary.

 

OVERVIEW

 

About Nuwellis

 

We are a medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The Company is focused on commercializing the Aquadex SmartFlow system for ultrafiltration therapy. The Aquadex SmartFlow system is indicated for temporary (up to eight hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics.

 

In August 2016, we acquired the Aquadex Business from a subsidiary of Baxter, a global leader in the hospital products and dialysis markets. On May 23, 2017, we announced that we were changing our name from Sunshine Heart, Inc. to CHF Solutions, Inc. to more appropriately reflect the direction of our business. On April 27, 2021, the Company announced that it was changing its name from CHF Solutions, Inc. to Nuwellis, Inc. to reflect the expansion of its customer base from treating fluid imbalance resulting from congestive heart failure to also include critical care and pediatrics applications.

 

Recent Developments

 

Nasdaq Compliance

 

On June 18, 2025, Nuwellis, Inc. (the “Company”) received a letter (the “Deficiency Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) informing the Company that because the closing bid price for the Company’s Common Stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company was not in compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The Deficiency Notice also indicated that the Company was not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) because the Company effected a reverse stock split over the prior one-year period or has effected one or more reverse stock splits over the prior two-year period with a cumulative ratio of 250 shares or more to one; accordingly, the Company was informed that its securities were subject to delisting from Nasdaq unless the Company timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). As previously disclosed, the Company effected the 2024 Reverse Stock Split on June 27, 2024. The Company timely requested a hearing before the Panel, which was scheduled for August 12, 2025. At its annual meeting held on May 20, 2025, the Company’s stockholders approved a proposal allowing the board of directors of the Company to effect a reverse split in the range of 1-for-5 to 1-for-70. The Company’s board of directors authorized the 2025 Reverse Stock Split to regain compliance with the Minimum Bid Price Requirement. On July 22, 2025, the Company received formal notice from Nasdaq stating that it has resolved the previously disclosed bid price deficiency. As a result, the hearing previously scheduled with the Nasdaq Hearings Panel for August 12, 2025, was cancelled, and shares of the Company’s Common Stock continue to be listed and traded on the Nasdaq Capital Market under the ticker “NUWE.”

 

Public Offering

 

On June 10, 2025, the Company announced the closing of its public offering of 61,444 shares of its Common Stock, pre-funded warrants to purchase 335,381 shares of Common Stock (all pre-funded warrants were exercised on this date), in each case with accompanying Series A Warrants to purchase up to 1,190,480 shares of Common Stock, Series B Warrants to purchase up to 396,829 shares of Common Stock and Placement Warrants to purchase up to 11,903 shares of Common Stock with gross proceeds of approximately $5.0 million, which included the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants. The public offering price per share of Common Stock and accompanying warrants is $12.60 per share and accompanying warrants, and the public offering price per pre-funded warrant and accompanying warrants is $12.5958 per pre-funded warrant and accompanying warrants. Each pre-funded warrant has an exercise price of $0.0042 per pre-funded warrant and was immediately exercisable. The Series B Warrants have an exercise price of $12.60 and will be exercisable for a period of five years following the receipt of stockholder approval which was obtained on August 4, 2025, as required by the applicable rules and regulations of Nasdaq. The Series A Warrants contain a one-time reset of the exercise price in the event that the Company implemented the 2025 Reverse Stock Split equal to the greater of: (i) 20% of the combined public offering price per share of Common Stock and accompanying warrants in the offering and (ii) the lowest daily volume weighted average price for the five trading days immediately following the date of the implementation of the 2025 Reverse Stock Split. After the reverse stock split effectuated on July 3, 2025, the reset exercise price of the Series A warrants was set at $7.00 per share and there were no further contractual exercise price adjustments following the reverse split. The Series B Warrants include a zero cash exercise option allowing holders of a Series B Warrant the right to receive, without payment of any additional cash to the Company, an aggregate number of shares equal to the number of shares of Common Stock that would be issuable upon a cash exercise of such Series B Warrants.

 

The Series A and B warrants offered in this financing were determined to be classified as a liability on the condensed consolidated balance sheet.  An independent valuation of the warrants was performed and reviewed with management.  The Series A warrants were valued using the Monte Carlo Simulation Model utilizing US Treasury Rates, Volatility rates, Common Stock price and assumptions around date and likelihood of a reverse split exercise price adjustment.  The Series B warrants were valued using the Common Stock price given the zero-exercise price.  The valuation at issuance was $10.6 million for the Series A warrants and $3.9 million for the Series B warrants, and on June 30, 2025, was $10.0 million for the Series A warrants and $3.7 million for the Series B warrants, representing a warrant liability decrease of $0.8 million from issuance. The $0.8 million warrant liability decrease from issuance has been reported on the condensed consolidated statement of operations as a “Change in fair value of warrant liability.”  The total warrant valuation of $14.5 million exceeded the gross proceeds of $5.0 million.  Accordingly, if the warrant valuation exceeds the gross proceeds, the difference will be recorded as “Day 1 interest.”  You will find this difference, along with other issuance costs (discounts, legal, printing) reported on the condensed consolidated statement of operations as “Financing expense.”

As a result of the above, the Company’s stockholders’ equity as of June 30, 2025, was below the Nasdaq Stockholders’ Equity Requirement.  However, subsequently the liability associated with the Series A Warrants of $8.4 million was reclassified on July 14, 2025, as equity due to the exercise price being reset to the floor at $7.00 per share.   The majority of the liability associated with the Series B Warrants has been removed as these were exercised into Common Stock.  As of September 30, 2025, there were 6,268 Series B warrants still unexercised and the fair value of these warrants was $21,004.

 

Contract with KDI

 

On May 12, 2025, the Company announced it had finalized an agreement with KDI Precision Manufacturing to support the next phase of Nuwellis’ growth. The Company made a contractual payment of $240,000 on July 15, 2025 to initiate the conversion of the production process to KDI. This strategic relationship is expected to expand Nuwellis' manufacturing capabilities, streamline operations, and enhance the company's ability to deliver high-quality products to healthcare providers and patients. Under the agreement, KDI will assume assembly responsibilities for the Aquadex SmartFlow® Console, AquaFlexFlow® Blood Circuits, and dELC® Catheters. To ensure a seamless transition and protect product expertise, current Nuwellis assembly employees will be hired by KDI. Sales, customer service, product design, and post-market surveillance will continue to reside within Nuwellis. During the third quarter, manufacturing and calibration of Consoles were moved to the KDI facility. As of October 20, 2025, all circuit and catheter manufacturing personnel (6 employees) had transitioned to the KDI facility and were converted to KDI employees.

 

Reverse Stock Split

 

On June 19, 2025, the Board approved the 2025 Reverse Stock Split. On July 2, 2025, the Company filed with the Secretary of State of the State of Delaware a Certificate of Amendment to its Certificate of Incorporation (the “Certificate of Amendment”) to effect the 2025 Reverse Stock Split, which became effective as of 5:00 p.m. Eastern Time on July 3, 2025, and the Company’s Common Stock began trading on a split-adjusted basis when the market opened on July 7, 2025. When the 2025 Reverse Stock Split became effective, every forty-two shares of the Company’s issued and outstanding Common Stock (and such shares held in treasury) automatically converted into one share of Common Stock, without any change in the par value per share. In addition, a proportionate adjustment was made to the per share exercise price and the number of shares issuable upon the conversion of the Company’s outstanding shares of preferred stock and exercise of all outstanding stock options, restricted stock units and warrants to purchase shares of Common Stock and the number of shares reserved for issuance pursuant to the Company’s equity incentive compensation plans. Any fraction of a share of Common Stock that was created as a result of the 2025 Reverse Stock Split was rounded down to the next whole share and the stockholder received cash equal to the market value of the fractional share, determined by multiplying such fraction by the closing sales price of the Company’s Common Stock as reported on Nasdaq on the last trading day before the 2025 Reverse Stock Split becomes effective. All share and per-share amounts have been retroactively adjusted to reflect the reverse stock splits for all periods presented.

 

REVERSE-HF Clinical Trial

 

On July 17, 2025, the Company announced the termination of its REVERSE-HF clinical trial, a randomized post-market trial evaluating ultrafiltration vs. IV loop diuretic therapy for fluid management in hospitalized heart failure patients. This decision reflects the Company’s strategic commitment to prioritize resources in areas demonstrating the greatest potential for patient impact and business growth—namely, outpatient heart failure, pediatric, and critical care. The Company anticipates it will save approximately $4.0M over the next 2.5 years by terminating the REVERSE-HF clinical trial.

 

International Operations

 

On August 7, 2025, the Company announced its decision to exit selected international operations in order to focus on the U.S. market—where the Company is seeing the strongest growth and clinical demand. This strategic realignment supports Nuwellis’ core business strategy: investing in the markets driving revenue growth. With expanding traction in U.S. cardiac surgery and pediatric programs, and a rising opportunity in the hospital-based outpatient space, the Company is streamlining to prioritize investment in markets where it can have the most immediate and long-term impact.

 

On August 19, 2025, the Company announced that it had entered into a non-binding letter of intent to acquire Rendiatech, Ltd., an Israeli-based medical device company specializing in real-time urine flow and acute kidney injury monitoring technologies. The proposed acquisition is expected to support the Company's strategy to expand its current technology platform beyond ultrafiltration by potentially adding continuous renal health monitoring technologies that provide clinicians with earlier insight into fluid status and kidney function. The parties are continuing discussion and due diligence.

 

At The Market Offering Agreement

 

On September 3, 2025, the Company entered into an At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. pursuant to which the Company may sell shares of the Company’s Common Stock, from time to time, at its option, through or to Ladenburg, as sales agent or principal. Sales of the Company’s Common Stock made pursuant to the Sales Agreement, were made under the Company’s Registration Statement on Form S-3 (File No. 333-280647) and the prospectus supplement filed on September 3, 2025 with the Securities and Exchange Commission, in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act, initially having an aggregate offering price of up to $4,650,000. Ladenburg will use its commercially reasonable efforts to sell the Common Stock from time to time, based upon the Company’s instructions (including any price, time, or size limits or other customary parameters or conditions the Company may impose). As of September 30, 2025, the Company had sold 447,288 of Common Shares for net proceeds of approximately $1.9 million. See Note 10 – Subsequent Event.

 

The Company is not obligated to make any sales of Common Stock under the Sales Agreement, and the Company cannot provide any assurances that it will issue any shares pursuant to the Sales Agreement. The offering of Common Stock pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement as permitted therein. The Company is obligated to pay Ladenburg an aggregate sales agent commission of up to 3.0% of the gross proceeds of the sale price for Common Stock sold under the Sales Agreement. The Company has also provided Ladenburg with customary indemnification rights and expense reimbursements for up to $50,000 of expenses in addition to ongoing diligence expenses. The representations, warranties and covenants contained in the Sales Agreement were made only for purposes of the Sales Agreement as of specific dates indicated therein, were solely for the benefit of Ladenburg and to allocate risk between the Company and Ladenburg, and as a result should not be relied on and may be subject to limitations agreed upon by the parties.

 

Executive Transition

 

Robert B. Scott resigned from the Company as Chief Financial Officer effective October 24, 2025. John L. Erb was appointed by the Company’s board of directors to serve as the interim Chief Financial Officer, the interim Principal Financial Officer, and interim Principal Accounting Officer.

 

CRITICAL ACCOUNTING POLICIES AND ESTIMATES

 

We have adopted various accounting policies to prepare the condensed consolidated financial statements in accordance with U.S. GAAP. Our most significant accounting policies are disclosed in Note 1 to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024.

 

The preparation of the condensed consolidated financial statements, in conformity with U.S. GAAP, requires us to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to stock-based compensation, valuation of equity and debt securities, and income tax reserves are updated as appropriate, which in most cases is quarterly. We base our estimates on historical experience, valuations, or various assumptions that are believed to be reasonable under the circumstances. There have been no material changes to our critical accounting policies and estimates from the information provided in Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2024.

 

Revenue Recognition: We recognize revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers. Accordingly, we recognize revenue when our customers obtain control of their products or services, in an amount that reflects the consideration that we expect to receive in exchange for those goods and services. See Note 2 – Revenue Recognition, included in Part I, Item 1 of this Quarterly Report on Form 10-Q, for additional disclosures.

 

Accounting for Warrants: We have issued and may continue to issue warrants to purchase shares of common and convertible preferred stock through our public and private offerings. We account for such warrants in accordance with ASC 480 Distinguishing Liabilities from Equity, which identifies three categories of freestanding financial instruments that are required to be accounted for as a liability. If determined to be classified as a liability, we will initially measure the fair value of the warrants upon issuance and subsequently remeasure the fair value of the warrants at each balance sheet date. If determined to be classified as equity, the fair value of the warrants will be measured as of the grant date and will not be subject to remeasurement at each balance sheet date.

 

The fair value of the warrant liability is estimated using a Monte Carlo simulation model using relevant inputs and assumptions based upon the terms of the warrants.

 

Loss per Share: Basic loss per share is computed based on the net loss for each period divided by the weighted average number of common shares outstanding. See Note 3 – Stockholders’ Equity below for additional disclosures.

 

Diluted earnings per share is computed based on the net loss allocable to Common Stockholders for each period divided by the weighted average number of common shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive common shares been issued, and reduced by the number of shares the Company could have repurchased from the proceeds from issuance of the potentially dilutive shares. Potentially dilutive shares of Common Stock include shares underlying outstanding convertible preferred stock, warrants, stock options and other stock-based awards granted under stock-based compensation plans.

 

Impairment of Long-Lived Assets: Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the impairment tests indicate that the carrying value of the asset or asset group is greater than the expected undiscounted cash flows to be generated by such asset or asset group, further analysis is performed to determine the fair value of the asset or asset group. To the extent the fair value of the asset or asset group is less than its carrying value, an impairment loss is recognized equal to the amount the fair value of the asset or asset group is exceeded by its carrying amount. Assets to be disposed of are carried at the lower of their carrying value or fair value less costs to sell. Considerable management judgment is necessary to estimate the fair value of assets or asset groups, and accordingly, actual results could vary significantly from such estimates.

 

The Company continues to report operating losses and negative cash flows from operations, both of which it considers to be indicators of potential impairment. Therefore, the Company evaluates its long-lived assets for potential impairment at each reporting period. The Company has concluded that its cash flows from the various long-lived assets are highly interrelated and, as a result, the Company consists of a single asset group. As the Company expects to continue incurring losses in the foreseeable future, the undiscounted cash flow step was bypassed, and the Company proceeded to measure fair value of the asset group. The Company has determined the fair value of the asset group associated with its loaner units by using expected cash flows estimating future discounted cash flows expected from the rental of these units. For recently acquired assets within the asset group, primarily equipment, the Company determined the fair value based on the replacement cost. There have been no impairment losses recognized for the three and nine month periods ended September 30, 2025 or the year ended December 31, 2024.

 

Going Concern: Our consolidated financial statements have been prepared and presented on a basis assuming we continue as a going concern. During the years ended December 31, 2024, and 2023, and through September 30, 2025, we incurred losses from operations and net cash outflows from operating activities as disclosed in the consolidated statements of operations and cash flows, respectively. As of September 30, 2025, we had an accumulated deficit of $313.9 million, and we expect to incur losses for the foreseeable future. To date, we have been funded by equity financings, and although we believe that we will be able to successfully fund our operations into the future, there can be no assurance that we will be able to do so or that we will ever operate profitably. These factors raise substantial doubt about the Company’s ability to continue as a going concern through at least twelve months from the report date.

 

We became a revenue-generating company after acquiring the Aquadex Business in August 2016. We expect to incur additional losses in the near-term as we grow the Aquadex Business, including investments in our sales and marketing capabilities, product development, purchasing inventory components, generating additional clinical evidence supporting the efficacy of the Aquadex System, and complying with the requirements related to being a U.S. public company. To become and remain profitable, we must succeed in expanding the adoption and market acceptance of the Aquadex System. This will require us to succeed in training personnel at hospitals and effectively and efficiently marketing and distributing the Aquadex System and related components. There can be no assurance that we will succeed in these activities, and we may never generate revenues sufficient to achieve profitability.

 

During 2021 and through September 30, 2025, we closed on underwritten public and other equity offerings for aggregate net proceeds of approximately $55.9 million after deducting the underwriting discounts and commissions or placement agents’ fees and offering expenses, as applicable, and other costs associated with the offerings. See Note 4 –Stockholders’ Equity, to the consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K. The Company will require additional funding to grow its business, which may not be available on terms favorable to the Company, or at all. The Company may receive those funds from the issuance of equity securities or other financing transactions. Should future capital raising be unsuccessful, the Company may not be able to continue as a going concern. No adjustments have been made relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company not continue as a going concern.

 

Understanding the near-term need to raise capital, in 2024, the Company undertook steps to reduce its monthly cash burn rate by approximately 40%, balanced against its strategic growth initiatives, which provided more flexibility in anticipation of tougher capital market conditions for microcap companies like Nuwellis. These reductions included, but were not limited to, a reduction of the salaries for members of senior management, no merit increases to the base salaries of any named executive officer or employee in 2024 for performance provided during the fiscal year ended December 31, 2023, no cash bonuses to any named executive officer or employee in 2024 for performance provided during the fiscal year ended December 31, 2023, a reduction in Board of Director and committee fees, temporary suspension of the Company’s 401(k) match, travel reductions, and reductions to select professional services. The Board authorized the restoration of the Company 401(k) match effective October 1, 2024, and the restoration of Board and committee fees and executive salaries, effective November 1, 2024.

 

We believe that our existing capital resources will be sufficient to support our operating plan into the first quarter of 2026; however, there can be no assurance that our capital resources will be sufficient through that time period. We will seek to raise additional capital to support our growth or other strategic initiatives through debt, equity, or a combination thereof. There can be no assurance the Company will be successful in raising additional capital.

 

NEW ACCOUNTING PRONOUNCEMENTS

 

In December 2023, FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. The new guidance is expected to improve income tax disclosures primarily related to the rate reconciliation and income taxes paid information by requiring 1) consistent categories and greater disaggregation of information in the rate reconciliation and 2) income taxes paid disaggregated by jurisdiction. The guidance is effective on a prospective basis, although retrospective application and early adoption is permitted. The Company is evaluating its disclosure approach for ASU 2023-09 and anticipates adopting the standard for the annual period ending December 31, 2025.

 

The Company has considered all recent accounting pronouncements issued and their potential effects on its consolidated financial statements. The Company's management believes that these recent pronouncements will not have a material effect on the Company's condensed consolidated financial statements.

 

FINANCIAL OVERVIEW

 

We are a medical technology company focused on commercializing the Aquadex System for ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy. Activities since inception have consisted principally of raising capital, performing research and development, and conducting pre-clinical and clinical studies. During 2016, we acquired the Aquadex business. Since then, our activities have consisted mainly of expanding our sales and marketing capabilities, performing clinical research, and engaging in new product development. The Company has an accumulated deficit since its inception and as of September 30, 2025, we had an accumulated deficit of $313.9 million. We expect to incur losses for the foreseeable future. To date, we have been funded by public financings. Although we believe that we will be able to continue to successfully fund our operations, there can be no assurance that we will be able to do so or that we will ever operate profitably.

 

Results of Operations

 

Comparison of three months ended September 30, 2025 to three months ended September 30, 2024

 

Net Sales

(in thousands)

 

 

 

Revenue is generated mainly from the sale of disposable blood filters and catheters used in conjunction with the Aquadex System consoles. We sell primarily in the United States to hospitals and clinics through our direct salesforce. We sell outside of the United States to independent specialty distributors, who in turn sell to hospitals and clinics in their geographic regions. The decrease in sales in the current year period is primarily due to one-time prior year SeaStar Medical Quelimmune revenue of $0.2 million, a decrease in international operations of $0.1 million year-over-year, and lower console average selling price, partially offset by a 15% increase in circuit sales.

 

Costs and Expenses

Our costs and expenses were as follows:

 

 

Cost of Goods Sold

The increase in cost of goods sold for the three months ended September 30, 2025, compared to the three months ended September 30, 2024, was primarily due to unfavorable manufacturing variances and under-absorption of fixed overhead because of lower production volumes earlier in the year, which flowed through Costs of Goods Sold in the current year quarter as that inventory was sold.

 

Selling, General and Administrative

The increase in selling, general and administrative expense was primarily driven by increased headcount and compensation-related expense and higher professional services fees.

 

Research and Development

The increase in R&D expenses was primarily driven by increased headcount and compensation-related expense and higher consulting fees associated with increased sustained engineering expense and improvements to our quality system.

 

 Comparison of nine months ended September 30, 2025 to nine months ended September 30, 2024

 

Net Sales

(in thousands)

 

 

Revenue is generated mainly from the sale of disposable blood filters and catheters used in conjunction with the Aquadex system consoles. We sell primarily in the United States to hospitals and clinics through our direct salesforce. We sell outside of the United States to independent specialty distributors who in turn sell to hospitals and clinics in their geographic regions. The decrease in sales in the current year period is primarily due to a 2% decrease in circuit sales, lower console average selling price, lower tech services and International, and one-time prior-year SeaStar Medical Quelimmune sales.

 

Costs and Expenses

Our costs and expenses were as follows:

 

 

Cost of Goods Sold

The increase in cost of goods sold for the nine months ended September 30, 2025, compared to the nine months ended September 30, 2024, was primarily due to unfavorable manufacturing variances and under-absorption of fixed overhead because of lower production volumes in the first half of fiscal year 2025.

 

Selling, General and Administrative

The decrease in selling, general and administrative expense was primarily driven by decreased headcount and compensation-related expense and lower professional services fees in the first half of fiscal year 2025.

 

Research and Development

The decrease in R&D expense versus the prior year was primarily driven by reduced R&D project spend.

 

Liquidity and Capital Resources

 

Sources of Liquidity

We have funded our operations primarily through cash on hand and a series of equity issuances.

 

On June 10, 2025, the Company announced the closing of its public offering of 61,444 shares of its Common Stock, pre-funded warrants to purchase 335,381 shares of Common Stock (all pre-funded warrants were exercised on this date), in each case with accompanying Series A Warrants to purchase up to 1,190,480 shares of Common Stock and Series B Warrants to purchase up to 396,829 shares of Common Stock with gross proceeds of approximately $5.0 million, which included the full exercise of the underwriter’s over-allotment option to purchase additional shares and warrants. The public offering price per share of Common Stock and accompanying warrants was $12.60 per share and accompanying warrants, and the public offering price per pre-funded warrant and accompanying warrants was $12.5958 per pre-funded warrant and accompanying warrants. Each pre-funded warrant has an exercise price of $0.0042 per pre-funded warrant and was immediately exercisable. The Series B Warrants have an exercise price of $12.60 and will be exercisable for a period of five years following the receipt of stockholder approval, as required by the applicable rules and regulations of Nasdaq. The Series A Warrants contain a one-time reset of the exercise price in the event that the Company implemented the 2025 Reverse Stock Split equal to the greater of: (i) 20% of the combined public offering price per share of Common Stock and accompanying warrants in the offering and (ii) the lowest daily volume weighted average price for the five trading days immediately following the date of the implementation of the 2025 Reverse Stock Split. After the reverse stock split effectuated on July 3, 2025, the reset exercise price of the Series A warrants was set at $7.00 per share. The Series B Warrants include a zero cash exercise option allowing holders of a Series B Warrant the right to receive, without payment of any additional cash to the Company, an aggregate number of shares equal to the number of shares of Common Stock that would be issuable upon a cash exercise of such Series B Warrants.

 

On September 3, 2025, the Company entered into a Sales Agreement with Ladenburg pursuant to which the Company may sell shares of the Company’s Common Stock, par value $0.0001 (the “Common Stock”), from time to time, at its option, through or to Ladenburg, as sales agent or principal. Sales of the Company’s Common Stock made pursuant to the Sales Agreement, were made under the Company’s Registration Statement on Form S-3 (File No. 333-280647) and the prospectus supplement filed on September 3, 2025 with the Securities and Exchange Commission, in sales deemed to be “at the market offerings” as defined in Rule 415 promulgated under the Securities Act, initially having an aggregate offering price of up to $4,650,000. Ladenburg will use its commercially reasonable efforts to sell the Common Stock from time to time, based upon the Company’s instructions (including any price, time, or size limits or other customary parameters or conditions the Company may impose). The Company is not obligated to make any sales of Common Stock under the Sales Agreement, and the Company cannot provide any assurances that it will issue any shares pursuant to the Sales Agreement. The offering of Common Stock pursuant to the Sales Agreement will terminate upon the termination of the Sales Agreement as permitted therein. The Company is obligated to pay Ladenburg an aggregate sales agent commission of up to 3.0% of the gross proceeds of the sale price for Common Stock sold under the Sales Agreement. The Company has also provided Ladenburg with customary indemnification rights and expense reimbursements for up to $50,000 of expenses in addition to ongoing diligence expenses. The representations, warranties and covenants contained in the Sales Agreement were made only for purposes of the Sales Agreement as of specific dates indicated therein, were solely for the benefit of Ladenburg and to allocate risk between the Company and Ladenburg, and as a result should not be relied on and may be subject to limitations agreed upon by the parties. As of September 30, 2025, 447,288 shares of Common Stock had sold with total net proceeds of approximately $1.9 million pursuant to the terms of the Sales Agreement. See Note 10 – Subsequent Events.

 

As of September 30, 2025, and December 31, 2024, cash and cash equivalents were $3.1 million and $5.1 million, respectively. Our business strategy and ability to fund our operations in the future depend in part on our ability to grow the Aquadex Business by expanding our salesforce, selling our products to hospitals and other healthcare facilities, and controlling costs. We will need to seek additional financing in the future, which, to date, has been primarily through offerings of our equity securities.

 

Cash Flows used in Operating Activities

Net cash used in operating activities was $7.7 million and $8.1 million for the nine months ended September 30, 2025, and September 30, 2024, respectively. The net cash used in each of these periods primarily reflects the net loss for those periods, partially offset by non-cash charges for stock-based compensation, depreciation and amortization, and revaluation of the warrant liability, and the effects of changes in operating assets and liabilities, including working capital.

 

Cash Flows used in Investing Activities

Net cash used in investing activities was $102,000 and $37,000 for the nine months ended September 30, 2025, and 2024, respectively. The cash used in investing activities in the current year period was for the purchase of loaner and demo console units and office equipment. The cash used in investing activities in the prior year period was for the purchase of manufacturing, laboratory, and office equipment.

 

Cash Flows provided by Financing Activities

Net cash provided by financing activities was $5.8 million and $6.2 million for the nine months ended September 30, 2025, and 2024, respectively. The cash provided by financing activities in the current year period was the result of proceeds received from the June 2025 financing and the September 2025 At-The-Marketing program. The cash provided by financing activities in the prior year period was the result of proceeds received from the April 2024, July 2024, and August 2024 financings and from the exercise of warrants from the October 2023 and April 2024 financings.

 

Capital Resource Requirements

As of September 30, 2025, we did not have any material commitments for capital expenditures.

 

Forward-Looking Statements and Risk Factors

 

Certain statements in this Quarterly Report on Form 10-Q are forward-looking statements within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), that are based on management’s beliefs, assumptions and expectations and information currently available to management. All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation, business development, and employees, our ability to execute on our strategic realignments, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, intellectual property protection, and other risks and uncertainties described in our filings with the SEC. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual events to adversely differ from the expectations indicated in these forward-looking statements, including without limitation, the risks and uncertainties described in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, in other reports filed thereafter with the SEC, which risk factors may by updated from time to time, and in this Quarterly Report on Form 10-Q for the quarter ended September 30, 2025. We operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risk factors and uncertainties. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation, the possibility that regulatory authorities do not accept our application or approve the marketing of our products, the possibility we may be unable to raise the funds necessary for the development and commercialization of our products, and those described in our filings with the SEC.

 

Not applicable.

 

 

Evaluation of Disclosure Controls and Procedures

 

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer (together, the “Certifying Officers”), as appropriate, to allow for timely decisions regarding required disclosure.

 

In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. The design of any system of controls is based, in part, upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.

 

As of September 30, 2025, the end of the period covered by this report, we conducted an evaluation, under the supervision and with the participation of management, including the Certifying Officers, of the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act. Our disclosure controls and procedures are designed to provide reasonable assurance of achieving their stated objectives. Based on their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective at a reasonable assurance level as of September 30, 2025. The Certifying Officers based their conclusion on the fact that the Company has identified two material weaknesses in controls over financial reporting, as detailed in the 2024 Annual Report on Form 10-K. In light of this fact, management expects to perform additional analyses, reconciliations, and remediations.

 

Changes in Internal Controls over Financial Reporting

 

There was no change in our internal control over financial reporting during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. However, as a result of the identified material weaknesses, changes in our internal control over financial reporting will occur.

 

PART II—OTHER INFORMATION

 

None.

 

You should carefully consider the risks and uncertainties we describe in our Annual Report on Form 10-K for the year ended December 31, 2024, and in other reports filed thereafter with the SEC, before deciding to invest in or retain shares of our Common Stock. There have been no material changes to the Risk Factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2024 other than those as set forth below.

 

Risks Related to Our Business

 

Nasdaq may delist our Common Stock from its exchange which could limit your ability to make transactions in our securities and subject us to additional trading restrictions.

 

Our Common Stock is listed on the Nasdaq Capital Market under the symbol “NUWE.” In order to maintain that listing, we must satisfy minimum financial and other requirements including, without limitation, the minimum stockholders’ equity requirement. There can be no assurances that we will be successful in maintaining, or if we fall out of compliance, in regaining compliance with the continued listing requirements and maintaining the listing of our Common Stock on the Nasdaq Capital Market.

 

In May 2024, the Company received a letter from the Listing Qualifications Staff (the “Staff”) informing the Company that it was not in compliance with the minimum stockholders’ equity requirement for continued listing on Nasdaq, under Listing Rule 5550(b)(1) (the “Stockholders’ Equity Requirement”).

 

After appearing before the Nasdaq Hearings Panel (the “Panel”) and presenting its plan of compliance for the Stockholders’ Equity Requirement to the Panel, the Company was notified on August 8, 2024 by Nasdaq that the Panel had granted the Company’s request for continued listing, subject to, among other things, the Company’s filing of its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, evidencing compliance with the Stockholders’ Equity Requirement. The letter also indicated that pursuant to Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a Mandatory Panel Monitor for a period of one year from the date of the letter. If, within that one-year monitoring period, the Staff found the Company out of compliance with the Stockholders’ Equity Requirement, the Company will not be permitted to provide the Staff with a plan of compliance with respect to the deficiency and the Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor would the Company be afforded an applicable cure or compliance period; instead, the Staff will issue a delisting letter and the Company will have the opportunity to request a new hearing, where the Company’s securities may be at that time subject to delisting.

 

On June 10, 2025, the Company closed an offering of 61,444 shares of its Common Stock, pre-funded warrants to purchase 335,381 shares of Common Stock, in each case with accompanying Series A Warrants to purchase up to 1,190,480 shares of Common Stock (“Series A Warrants”) and Series B Warrants to purchase up to 396,829 shares of Common Stock (“Series B Warrants,” collectively, the “June 2025 Offering”). The public offering price per share of Common Stock and accompanying warrants is $12.60 per share and accompanying warrants, and the public offering price per pre-funded warrant and accompanying warrants is $12.5958 per pre-funded warrant and accompanying warrants. The Series B Warrants had an exercise price of $12.60 and would be exercisable for a period of five years following the receipt of stockholder approval, which was obtained on August 4, 2025, as required by the applicable rules and regulations of Nasdaq. The Series A Warrants contain a one-time reset of the exercise price in the event that the Company implemented the 2025 Reverse Stock Split equal to the greater of: (i) 20% of the combined public offering price per share of Common Stock and accompanying warrants in the offering and (ii) the lowest daily volume weighted average price for the five trading days immediately following the date of the implementation of the 2025 Reverse Stock Split.

 

As a result of specific terms included in the Series A Warrants and the Series B Warrants, it was determined that outstanding Series A Warrants and the Series B Warrants should be classified as a liability on the Company’s balance sheet until (i) in the case of the Series A Warrants, the price reset is triggered in connection with the reverse split or (ii) the warrants are exercised for shares of Common Stock. As of September 30, 2025, the liability associated with the Series A Warrants has been reclassified as equity and a majority of the liability associated with the Series B Warrants has been removed due to the exercise of the Series B Warrants for shares of Common Stock.

 

On July 3, 2025, the Company consummated a one-for-forty-two reverse stock split of the Company’s issued and outstanding shares of Common Stock. As a result of this reverse stock split, the price reset provision of the Series A Warrants was triggered, resulting in the exercise price being reduced to $7.00 per share, and the transition of any outstanding Series A Warrants from being classified as a liability on the Company’s balance sheet into equity. On August 4, 2025 at a special meeting our stockholders approved, amongst other things, the exercise of the Series A and Series B Warrants in accordance with Nasdaq Listing Rule 5635(d). Following this special meeting, the holders of the Series B Warrants exercised a majority of the outstanding warrants, resulting in the removal of a majority of the liability associated with the outstanding Series B Warrants from the Company’s balance sheet.

 

We continue to actively monitor our performance with respect to the listing standards and will consider available options to resolve any deficiency and maintain compliance with the Nasdaq rules. There can be no assurance that we will be able to maintain compliance or, if we fall out of compliance, regain compliance with any deficiency, or if we implement an option that regains our compliance, maintain compliance thereafter.

 

If our Common Stock is delisted from Nasdaq, our ability to raise capital through public offerings of our securities and to finance our operations could be adversely affected. We also believe that delisting would likely result in decreased liquidity and/or increased volatility in our Common Stock and could harm our business and future prospects. In addition, we believe that, if our Common Stock is delisted, our stockholders would likely find it more difficult to obtain accurate quotations as to the price of the Common Stock and it may be more difficult for stockholders to buy or sell our Common Stock at competitive market prices, if at all. If our Common Stock is delisted by Nasdaq, the price of our Common Stock may decline and our Common Stock may be eligible to be quoted on the OTC Bulletin Board, another over-the-counter quotation system, or on the pink sheets, which would negatively affect the liquidity of our Common Stock and an investor may find it more difficult to dispose of their Common Stock or obtain accurate quotations as to the market value of our Common Stock. Any such delisting action may materially adversely affect our ability to raise capital or pursue strategic transactions on acceptable terms, or at all.

 

If we fail to comply with federal and state laws regarding off-label use of our products, we could face substantial civil and criminal penalties and our business, financial condition, results of operations, and prospects could be adversely affected.

 

Healthcare professionals may choose to use and prescribe medical devices for uses that are not described in the product’s labeling and for uses that differ from those tested in clinical trials and approved or cleared by the regulatory authorities. Medical device companies, however, are prohibited from marketing and promoting products for indications and uses that are not specifically approved or cleared by FDA. Such “off-label” uses are common in the medical world and often are appropriate treatments for some patients. Regulatory authorities in the U.S. generally do not restrict or regulate the treatment choices of healthcare professionals. Regulatory authorities do, however, restrict communications by companies concerning off-label uses of their products. Any FDA clearance or marketing authorization that we have or may obtain in the future permits us to promote the subject medical device only for the specific use(s) cleared, approved, certified or otherwise authorized. We are prohibited from marketing or promoting any medical devices for off-label use.

 

Notwithstanding the regulatory restrictions on off-label promotion, the FDA and other regulatory authorities allow companies to engage in truthful, non-misleading, and non-promotional speech concerning their products. Accordingly, we engage in medical education activities and communicate with healthcare professionals about many aspects of our products and clinical trials. In addition, we are aware that the Aquadex System, which is cleared by the FDA solely for use in adults and pediatric patients weighing 20 kg or more, is being used off-label to treat patients who weigh less than 20 kg, including being modified by children’s hospitals so that it can provide dialysis to neonates and other premature infants who were born either without kidneys or without normal kidney function. These patients typically have very few other treatment options given the large extracorporeal blood volume required by standard dialysis machines, the need for blood priming of the dialysis circuit and the use of large catheters.

 

Although we believe that all of our communications regarding off-label uses are in compliance with the relevant regulatory requirements, the FDA or another regulatory authority may disagree, and characterize such communications as marketing and promotion of an off-label use.

 

If the FDA determines that we have marketed or promoted our products for off-label use by us or our commercial partners, it could request that we or our commercial partners modify those promotional materials. We also could be subject to regulatory or enforcement actions, including the issuance of untitled letters or warning letters, injunctions, seizures, civil fines and criminal penalties.

 

In addition to FDA, we may be subject to significant enforcement actions from other federal and state enforcement authorities, such as the Department of Justice and the Office of the Inspector General of the Department of Health and Human Services, if they consider our communications, including promotional and training materials, to constitute promotion of an uncleared, uncertified or unapproved use of a medical device. In the U.S., engaging in the impermissible promotion of our products, following approval, for off-label uses can also subject us to false claims and other litigation under federal and state statutes, including fraud and abuse and consumer protection laws, which can lead to civil and criminal penalties and fines, agreements with governmental authorities that materially restrict the manner in which we promote or distribute therapeutic products and do business through, for example, corporate integrity agreements, suspension or exclusion from participation in federal and state healthcare programs, and debarment from government contracts and refusal of future orders under existing contracts. These laws include the federal False Claims Act, which allows any individual to bring a lawsuit against a company on behalf of the federal government alleging submission of false or fraudulent claims or causing others to present such false or fraudulent claims, for payment by a federal program such as Medicare or Medicaid. If the government decides to intervene and prevails in the lawsuit, the individual will share in the proceeds from any fines or settlement funds. If the government declines to intervene, the individual may pursue the case alone. Many False Claims Act lawsuits against, and preceding investigations of, manufacturers of healthcare products are brought every year, leading to several substantial civil and criminal settlements related to off-label uses. In addition, False Claims Act lawsuits may expose manufacturers to follow-on claims by private payors based on fraudulent marketing practices. This growth in litigation has increased the risk that a company will have to defend a false claim action, pay settlement fines or restitution, as well as criminal and civil penalties, agree to comply with burdensome reporting and compliance obligations, and be excluded from Medicare, Medicaid, or other federal and state healthcare programs. If we or our collaborators do not lawfully promote our approved products, we may become subject to such investigations and litigation and, if we do not successfully defend against such actions, those actions may have a material adverse effect on our business, financial condition, results of operations and prospects.

 

Additionally, we must have adequate substantiation for the claims we make for our products and services. If any of our claims are determined to be false, misleading or deceptive, our products and services could be considered misbranded under the Food Drug and Cosmetic Act or in violation of the Federal Trade Commission Act. We could also face lawsuits from our competitors under the Lanham Act alleging that our marketing materials are false or misleading.

 

Foreign jurisdictions have their own laws and regulations concerning medical devices, including marketing authorizations and certifications, communications about off-label uses, and substantiation of advertising and promotional claims. Failure to comply with those laws and regulations could result in actions against us, including fines, penalties and exclusion from the market. Any such actions could adversely effect our ability to market new products and services or continue to market existing products and services in those jurisdictions.

 

Changes to U.S. tariff and import/export regulations may have a negative effect on our suppliers and/or service providers and, in turn, could have a material adverse impact on our financial condition.

 

The United States has recently enacted and proposed to enact significant new tariffs. Additionally, President Trump has directed various federal agencies to further evaluate key aspects of U.S. trade policy and there has been ongoing discussion and commentary regarding potential significant changes to U.S. trade policies, treaties and tariffs. There continues to exist significant uncertainty about the future relationship between the United States and other countries with respect to such trade policies, treaties and tariffs. These developments, or the perception that any of them could occur, may have a material adverse effect on global economic conditions and the stability of global financial markets, and may significantly impact the cost of the Aquadex System, and other parts and supplies sourced internationally or impact the cost of service providers located outside of the United States, which in turn would negatively impact us. We currently source certain raw materials of the Aquadex System from China and are monitoring possible tariff impacts.

 

Changes in U.S. federal government funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, properly administer drug innovation, or prevent new products and services from being developed or commercialized, which could negatively impact our business.

 

The ability of the FDA to review and approve new products can be affected by a variety of factors, including budget and funding levels, the ability to hire and retain key personnel, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.

 

The ability of the FDA and other government agencies to properly administer their functions is highly dependent on the levels of government funding and the ability to fill key leadership appointments, among various factors. Delays in filling or replacing key positions could significantly impact the ability of the FDA and other agencies to fulfill their functions and could greatly impact healthcare and the drug industry.

 

However, any future government proposals to reduce or eliminate budgetary deficits may include reduced allocations to the FDA and other related government agencies. These budgetary pressures may result in a reduced ability by the FDA to perform its respective roles and may have a related impact on academic institutions and research laboratories whose funding is fully or partially dependent on both the level and the timing of funding from government sources. Robert F. Kennedy Jr., the current Secretary of the U.S. Department of Health and Human Services, which oversees the FDA has previously stated his intent to downsize or restructure this agency, including by appointing new directors to the agencies. We cannot anticipate the effect that any such restructuring or new appointments may have on our business.

 

Disruptions at the FDA and other agencies, such as those resulting from a restructuring of these agencies, a government shutdown, or uncertainty from stopgap spending bills may slow the time necessary for new drugs and devices to be reviewed and/or approved by necessary government agencies and may affect the ability of the healthcare and drug industries to deliver new products to the market in a timely manner, which would adversely affect our operating results and business.

 

If we experience an interruption in supply from a material sole source supplier, our business may be harmed.

 

We are dependent on sole source suppliers to produce raw materials including our one fully validated third-party sterilizer. If there is any interruption in supply of our raw materials from these sole source suppliers, for any reason, there can be no assurance that we will be able to obtain adequate alternative quantities of the raw materials within a reasonable time or at commercially reasonable prices. Our suppliers could discontinue the manufacturing or supply of these components at any time.

 

We do not carry a significant inventory of some of these components. Our suppliers may not be able to meet our demand for their products, either because of acts of nature, the nature of our agreements with those suppliers or our relative importance to them as a customer, and our suppliers may decide in the future to discontinue or reduce the level of business they conduct with us. In addition, if these suppliers are unable to deliver components to us, whether due to a labor shortage, slow-down or stoppage, or for any other reason, we would be required to seek alternative suppliers. We might not be able to identify and qualify additional or replacement suppliers for any of these components quickly or at all or without incurring significant additional costs.

 

We cannot guarantee that we will be able to establish and validate alternative relationships on similar terms, without delay or at all. Finding and validating alternative suppliers may not be feasible or could take a significant amount of time and involve significant expense, and any such delay could significantly harm our business resulting in backorders, production delays and rationing end-user product availability. While we have taken steps to attempt to mitigate the impact of potential supply shortages, a future shortage may have a negative impact on our ability to manufacture our products and harm our business.

 

 

There were no unregistered sales of equity securities during the quarter ended September 30, 2025.

 

 

Not applicable.

 

 

Not applicable.

 

 

None of the Company’s directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted, modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company’s three months ended September 30, 2025, as such terms are defined under Item 408(a) of Regulation S-K.

 

 

The exhibits filed as part of this Quarterly Report on Form 10-Q are listed in the Exhibit Index below.

 

Exhibit Index

Nuwellis, Inc.

Form 10-Q for the Quarterly Period Ended September 30, 2025

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

31

0.024 0001506492 false Q3 --12-31 0001506492 2025-01-01 2025-09-30 0001506492 2025-11-07 0001506492 2025-09-30 0001506492 2024-12-31 0001506492 nuwe:SeriesJConvertiblePreferredStockMember 2025-09-30 0001506492 nuwe:SeriesJConvertiblePreferredStockMember 2024-12-31 0001506492 us-gaap:SeriesAPreferredStockMember 2025-09-30 0001506492 us-gaap:SeriesAPreferredStockMember 2024-12-31 0001506492 us-gaap:SeriesFPreferredStockMember 2025-09-30 0001506492 us-gaap:SeriesFPreferredStockMember 2024-12-31 0001506492 nuwe:SeriesF1ConvertiblePreferredStockMember 2025-09-30 0001506492 nuwe:SeriesF1ConvertiblePreferredStockMember 2024-12-31 0001506492 2025-07-01 2025-09-30 0001506492 2024-07-01 2024-09-30 0001506492 2024-01-01 2024-09-30 0001506492 us-gaap:CommonStockMember 2023-12-31 0001506492 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0001506492 us-gaap:RetainedEarningsMember 2023-12-31 0001506492 2023-12-31 0001506492 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001506492 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-03-31 0001506492 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001506492 2024-01-01 2024-03-31 0001506492 nuwe:SeriesJPreferredStockMember us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001506492 nuwe:SeriesJPreferredStockMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001506492 nuwe:SeriesJPreferredStockMember us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-03-31 0001506492 nuwe:SeriesJPreferredStockMember us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001506492 nuwe:SeriesJPreferredStockMember 2024-01-01 2024-03-31 0001506492 us-gaap:CommonStockMember 2024-03-31 0001506492 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 0001506492 us-gaap:RetainedEarningsMember 2024-03-31 0001506492 2024-03-31 0001506492 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001506492 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2024-04-01 2024-06-30 0001506492 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001506492 2024-04-01 2024-06-30 0001506492 us-gaap:CommonStockMember 2024-06-30 0001506492 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2024-06-30 0001506492 us-gaap:RetainedEarningsMember 2024-06-30 0001506492 2024-06-30 0001506492 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001506492 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2024-07-01 2024-09-30 0001506492 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001506492 us-gaap:CommonStockMember 2024-09-30 0001506492 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0001506492 us-gaap:RetainedEarningsMember 2024-09-30 0001506492 2024-09-30 0001506492 us-gaap:CommonStockMember 2024-12-31 0001506492 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2024-12-31 0001506492 us-gaap:RetainedEarningsMember 2024-12-31 0001506492 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001506492 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2025-01-01 2025-03-31 0001506492 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001506492 2025-01-01 2025-03-31 0001506492 us-gaap:CommonStockMember 2025-03-31 0001506492 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2025-03-31 0001506492 us-gaap:RetainedEarningsMember 2025-03-31 0001506492 2025-03-31 0001506492 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001506492 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2025-04-01 2025-06-30 0001506492 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001506492 2025-04-01 2025-06-30 0001506492 us-gaap:CommonStockMember 2025-06-30 0001506492 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2025-06-30 0001506492 us-gaap:RetainedEarningsMember 2025-06-30 0001506492 2025-06-30 0001506492 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001506492 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2025-07-01 2025-09-30 0001506492 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001506492 us-gaap:CommonStockMember 2025-09-30 0001506492 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001506492 us-gaap:AccumulatedTranslationAdjustmentMember 2025-09-30 0001506492 us-gaap:RetainedEarningsMember 2025-09-30 0001506492 nuwe:SeriesJConvertiblePreferredStockMember 2025-01-01 2025-09-30 0001506492 nuwe:SeriesJConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001506492 nuwe:SeriesF1ConvertiblePreferredStockMember 2025-01-01 2025-09-30 0001506492 nuwe:SeriesF1ConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001506492 us-gaap:SalesMember 2025-07-01 2025-09-30 0001506492 nuwe:CustomerOneMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2025-07-01 2025-09-30 0001506492 nuwe:CustomerTwoMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2025-07-01 2025-09-30 0001506492 us-gaap:SalesMember 2025-01-01 2025-09-30 0001506492 nuwe:CustomerOneMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-09-30 0001506492 us-gaap:SalesMember 2024-07-01 2024-09-30 0001506492 nuwe:CustomerOneMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001506492 nuwe:CustomerTwoMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001506492 us-gaap:SalesMember 2024-01-01 2024-09-30 0001506492 nuwe:CustomerOneMember us-gaap:SalesMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001506492 us-gaap:AccountsReceivableMember 2025-01-01 2025-09-30 0001506492 nuwe:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-09-30 0001506492 nuwe:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-09-30 0001506492 us-gaap:AccountsReceivableMember 2024-01-01 2024-12-31 0001506492 nuwe:CustomerOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001506492 nuwe:CustomerTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001506492 us-gaap:StockOptionMember 2025-01-01 2025-09-30 0001506492 us-gaap:StockOptionMember 2024-01-01 2024-09-30 0001506492 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001506492 us-gaap:WarrantMember 2024-01-01 2024-09-30 0001506492 us-gaap:SeriesFPreferredStockMember 2025-01-01 2025-09-30 0001506492 us-gaap:SeriesFPreferredStockMember 2024-01-01 2024-09-30 0001506492 nuwe:SeriesF1ConvertiblePreferredStockMember 2025-01-01 2025-09-30 0001506492 nuwe:SeriesF1ConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001506492 nuwe:SeriesJConvertiblePreferredStockMember 2025-01-01 2025-09-30 0001506492 nuwe:SeriesJConvertiblePreferredStockMember 2024-01-01 2024-09-30 0001506492 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:TransferredOverTimeMember 2025-07-01 2025-09-30 0001506492 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:TransferredOverTimeMember 2024-07-01 2024-09-30 0001506492 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:TransferredOverTimeMember 2025-01-01 2025-09-30 0001506492 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:TransferredOverTimeMember 2024-01-01 2024-09-30 0001506492 srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:TransferredOverTimeMember 2024-07-01 2024-09-30 0001506492 srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:TransferredOverTimeMember 2024-01-01 2024-09-30 0001506492 srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:TransferredOverTimeMember 2025-07-01 2025-09-30 0001506492 srt:MaximumMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:TransferredOverTimeMember 2025-01-01 2025-09-30 0001506492 2025-10-01 2025-09-30 0001506492 us-gaap:SeriesFPreferredStockMember 2025-01-01 2025-09-30 0001506492 us-gaap:SeriesFPreferredStockMember 2017-11-27 0001506492 us-gaap:SeriesFPreferredStockMember 2017-11-27 2017-11-27 0001506492 us-gaap:SeriesFPreferredStockMember 2025-07-07 0001506492 us-gaap:SeriesFPreferredStockMember 2025-06-06 0001506492 nuwe:SeriesF1ConvertiblePreferredStockMember 2025-06-09 2025-06-09 0001506492 nuwe:SeriesF1ConvertiblePreferredStockMember 2025-06-09 0001506492 us-gaap:CommonStockMember nuwe:June2025StockOfferingMember 2025-06-10 2025-06-10 0001506492 us-gaap:CommonStockMember nuwe:June2025StockOfferingMember 2025-06-10 0001506492 srt:MaximumMember nuwe:SeriesAWarrantsMember nuwe:June2025StockOfferingMember 2025-06-10 0001506492 srt:MaximumMember nuwe:SeriesBWarrantsMember nuwe:June2025StockOfferingMember 2025-06-10 0001506492 srt:MaximumMember nuwe:PlacementWarrantsMember nuwe:June2025StockOfferingMember 2025-06-10 0001506492 us-gaap:CommonStockMember nuwe:June2025StockOfferingMember 2025-06-10 2025-06-10 0001506492 us-gaap:CommonStockMember nuwe:June2025StockOfferingMember 2025-06-10 0001506492 nuwe:June2025StockOfferingMember 2025-06-10 0001506492 nuwe:SeriesBWarrantsMember nuwe:June2025StockOfferingMember 2025-06-10 0001506492 nuwe:SeriesBWarrantsMember nuwe:June2025StockOfferingMember 2025-01-01 2025-09-30 0001506492 nuwe:SeriesAWarrantsMember nuwe:June2025StockOfferingMember 2025-06-10 2025-06-10 0001506492 nuwe:SeriesAWarrantsMember nuwe:June2025StockOfferingMember 2025-07-03 0001506492 nuwe:SeriesBWarrantsMember nuwe:June2025StockOfferingMember 2025-07-03 0001506492 nuwe:SeriesAWarrantsMember nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2025-06-10 0001506492 nuwe:SeriesBWarrantsMember nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2025-06-10 0001506492 nuwe:SeriesAWarrantsMember nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2025-06-30 0001506492 nuwe:SeriesBWarrantsMember nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2025-06-30 0001506492 nuwe:SeriesAAndBWarrantsMember nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2025-06-30 2025-06-30 0001506492 nuwe:SeriesAAndBWarrantsMember nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2025-06-10 2025-06-10 0001506492 nuwe:SeriesAAndBWarrantsMember nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2025-06-10 0001506492 nuwe:SeriesAWarrantsMember 2025-07-14 2025-07-14 0001506492 nuwe:SeriesAWarrantsMember 2025-07-14 0001506492 nuwe:SeriesBWarrantsMember 2025-09-30 0001506492 nuwe:SeriesBWarrantsMember 2025-01-01 2025-09-30 0001506492 2025-06-19 2025-06-19 0001506492 srt:MaximumMember nuwe:AtTheMarketOfferingMember 2025-09-03 2025-09-03 0001506492 nuwe:AtTheMarketOfferingMember 2025-01-01 2025-09-30 0001506492 srt:MaximumMember 2025-09-30 0001506492 srt:MaximumMember 2025-01-01 2025-09-30 0001506492 us-gaap:EmployeeStockOptionMember 2025-07-01 2025-09-30 0001506492 us-gaap:EmployeeStockOptionMember 2024-07-01 2024-09-30 0001506492 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-09-30 0001506492 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001506492 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2025-07-01 2025-09-30 0001506492 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-01 2024-09-30 0001506492 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2025-01-01 2025-09-30 0001506492 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0001506492 us-gaap:ResearchAndDevelopmentExpenseMember 2025-07-01 2025-09-30 0001506492 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001506492 us-gaap:ResearchAndDevelopmentExpenseMember 2025-01-01 2025-09-30 0001506492 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001506492 nuwe:SeriesAWarrantsMember 2025-09-30 0001506492 nuwe:SeriesAWarrantsMember 2024-12-31 0001506492 nuwe:SeriesBWarrantsMember 2024-12-31 0001506492 nuwe:SeriesJWarrantsMember 2025-09-30 0001506492 nuwe:SeriesJWarrantsMember 2024-12-31 0001506492 nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2023-12-31 0001506492 nuwe:SeriesJWarrantsMember nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2024-01-01 2024-12-31 0001506492 nuwe:April242024WarrantsIssuanceMember nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2024-01-01 2024-12-31 0001506492 nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2024-12-31 0001506492 nuwe:June102025WarrantsIssuanceMember nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2025-01-01 2025-09-30 0001506492 nuwe:SeriesAWarrantsMember nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2025-01-01 2025-09-30 0001506492 nuwe:SeriesBWarrantsMember nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2025-01-01 2025-09-30 0001506492 nuwe:AdditionalPaidInCapitalAttributableToConvertibleOptionMember 2025-09-30 0001506492 srt:MinimumMember 2025-01-01 2025-09-30 0001506492 nuwe:FluidOverloadMember 2025-07-01 2025-09-30 0001506492 nuwe:FluidOverloadMember 2024-07-01 2024-09-30 0001506492 nuwe:FluidOverloadMember 2025-01-01 2025-09-30 0001506492 nuwe:FluidOverloadMember 2024-01-01 2024-09-30 0001506492 nuwe:AtTheMarketOfferingMember 2025-09-03 2025-09-03 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure nuwe:Customer nuwe:Sqft nuwe:Segment